References
- Nahin, RL. 2015. Estimates of pain prevalence and severity in adults:
United States, 2012. J Pain 16(8):769-80.
- Chau, D.L., Walker, V., Pai, L., Cho, L.M. 2008. Opiates and elderly:
use and side effects. Clin Interv Aging 3(2): 273-8.
- CPIC® Guideline for Codeine and CYP2D6. Retrieved 2018 from
https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/
- Samer, C.F., Daali, Y, Wagner, M., Hopfgartner, G., Eap, C.B., et al.
2010. Genetic polymorphisms and drug interactions modulating CYP2D6
and CYP3A activities have a major effect on oxycodone analgesic
efficacy and safety. Br J Pharmacol 160(4): 919–30.
- Samer, C.F., Daali, Y, Wagner, M., Hopfgartner, G., Eap, C.B., et al.
2010. The effects of CYP2D6 and CYP3A activities on the
pharmacokinetics of immediate release oxycodone. Br J Pharmacol
160(4): 907–18.
- Stamer, U.M., Lehnen, K., Höthker. F., Bayerer, B., Wolf, S., et al.
2003. Impact of CYP2D6 genotype on postoperative tramadol analgesia.
Pain 105(1-2):231–8.
- Takahashi, P., Ryu, E., Pathak, J., Jenkins, G.D., Batzler, A., et al.
2017. Increased risk of hospitalization for ultrarapid metabolizers of
cytochrome P450 2D6. Pharmgenomics Pers Med 10: 39–47.
- Doan, J., Zakrzewski-Jakubiak, H., Roy, J., Turgeon, J., Tannenbaum,
C. 2013. Prevalence and risk of potential cytochrome P450-medicated
drug-drug interactions in older hospitalized patients with
polypharmacy. Ann Pharmacother 47(3):324-32.
- Codeine sulfate [Package Insert]. Eatontown, NJ: West Ward
Pharmaceutical Corp: October 2019.
Table 1: Adapted CPIC Recommendations to Guide Codeine and
Possibly Alternative Opioid Therapy Using PGx
Information 2